Atlas market file · Equity · United States
Inventiva S.A.IVA
- Last close
- 4.8
- Change
- +3.00%
- 96-bar range
- 3.35 – 6.245
- As of
- 7 Aug 2026
Inventiva S.A. is a pharmaceutical preparations issuer listed as IVA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
IVA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+100.00% over the window).
Source rail: Yahoo Finance chart API (IVA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for IVA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
IVA public profile
Pharmaceutical preparations issuer. Inventiva S.A. is connected to current market context, cited company sources and its retained research file.
Inventiva S.A. trades as IVA on NASDAQ. Inventiva S.A. (IVA) has a latest verified close of 4.8, up 3.00%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files IVA under USA Stocks for browsing.
What changed for Inventiva S.A. today
Inventiva S.A. (Euronext: IVA) kicked off July with a scientific flourish, publishing proof-of-concept trial results for lanifibranor in Type 2 diabetes and MASLD patients in the Journal of Hepatology. The drug, designed to tackle the ‘full biological complexity’ of MASH, showed enough promise to keep the narrative alive-even as the company’s H1 2025 financials revealed a cash position of €68.2 million and revenues of €3.8 million, a stark contrast to the glossy lab imagery on its investor relations page.
The French biotech’s story remains anchored in its pipeline: lanifibranor, an oral pan-PPAR agonist, is its lone Phase IIb asset, with no approved products generating revenue. The company’s recent EIB warrant restructuring-a financial Hail Mary-issued new warrants to extend liquidity, but this dilutive maneuver keeps the ‘promotional risk’ flag firmly planted. With R&D costs swallowing 85% of H1 2025 revenues, Inventiva’s survival hinges on partnership deals or a miracle in Phase III.
Chart-wise, IVA’s equity is a penny-stock rollercoaster, trading between €0.80 and €2.50 over the past year on Euronext. The lack of revenue diversification and reliance on a single candidate make this a binary play: either lanifibranor becomes a blockbuster, or the cash runway (18-24 months at current burn) becomes a going-concern footnote. The recent publication in Nature Communications offers a temporary credibility boost, but the market awaits harder evidence-like a big-pharma cheque or a regulatory breakthrough.
Sources & evidence · 5 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
IVA technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on IVA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep IVA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
IVA FAQ
What is Inventiva S.A. (IVA)?Inventiva S.A. (IVA) has a latest verified close of 4.8, up 3.00%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Inventiva S.A. (IVA) has a latest verified close of 4.8, up 3.00%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for IVA?Inventiva S.A. (IVA) has a latest verified close of 4.8, up 3.00%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Inventiva S.A. (IVA) has a latest verified close of 4.8, up 3.00%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files IVA under USA Stocks for browsing.
How often is the IVA page updated?The IVA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The IVA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for IVA?The IVA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:IVA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The IVA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:IVA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on IVA?Yes. The workstation can open IVA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open IVA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this IVA page investment advice?No. The IVA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The IVA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →